Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Source: SeekingAlpha
2026-02-19 11:28:56 ET
Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article , " Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
0.21% G/L:
$228.2209 Last:
2,045,501 Volume:
$226.05 Open:
ABBV Latest News
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
